Trial on DIM

purple32

Anyone on this clinical trial ? I was doing a  google search on trials for DIM last night and came across it.

Sorry I lost the link, but it would come up in a google or else

clinicaltrials.gov  I believe.

luv_gardening

I found two trials that are recruiting:

Diindolylmethane Efficacy Study

Diindolylmethane in Treating Patients With Breast Cancer
This study is currently recruiting participants.
Verified May 2011 by University of Arizona

This phase II/III trial studies how well diindolylmethane (DIM) works and compares it to placebo in treating patients with breast cancer. DIM may slow the growth of tumor cells and be an effective treatment for breast cancer.
Official Title: Evaluation of Diindolylmethane Supplementation to Modulate Tamoxifen Efficacy in Breast Cancer The Diindolylmethane Efficacy Study

Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery

This study is currently recruiting participants.
Verified June 2012 by Barbara Ann Karmanos Cancer Institute Detroit, Michigan

This study is being done to find out whether a nutritional supplement, called BioResponse-DIM (BR-DIM [oral microencapsulated diindolylmethane]), improves the survival for women who have residual cancer cells following surgery after chemotherapy for breast cancer. BR-DIM is an active ingredient in cruciferous vegetables (broccoli, brussels sprouts and cauliflower). Consumption of these vegetables has been associated with a decreased risk in several cancers. Researchers also hope to find out whether different biomarkers (also called "markers") in the blood predict the chance of breast cancer returning. BR-DIM is thought to be effective in treating stage II-III breast cancer that is triple negative, AR positive (+), and where there is residual cancer cells in the breast after chemotherapy.

Official Title: A Pilot Study of BR-DIM in Women With Stage II-III, Triple Negative, and Androgen Receptor Positive, Invasive Breast Cancer, Who Have Residual Disease Following Surgical Resection After Neoadjuvant Chemotherapy

U.S. National Library of Medicine -  ClinicalTrials.gov